Appearing as a promising advance in the battle against obesity, the drug is capturing considerable buzz. It combines the action of two recognized GLP-1 binding agonists, semaglutide , and an unique glucose-dependent incretin component. Early patient results have shown substantial fat reduction in people with a high BMI , potentially offering a … Read More